Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06955169 · ClinicalTrials.gov registry record · Phase 2
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
A Phase 2 study of Intracranial Meningioma, sponsored by RTOG Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 3
- Study locations
NCT06955169 is a Phase 2 study of Intracranial Meningioma that is actively recruiting participants, run by RTOG Foundation. The registered enrollment target is 153 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06955169, a Phase 2 study of Intracranial Meningioma, is actively recruiting participants, sponsored by RTOG Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Conditions Studied
Interventions
- DRUG [177Lu]Lu-DOTATATE
- OTHER Standard of Care treatments
Study Locations (3)
Florida
- Baptist Health Medical Group Oncology - Miami
Georgia
- Piedmont Healthcare - Atlanta
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2025-12-24 |
| Est. Completion | 2030-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06955169
The ClinicalTrials.gov registry entry for NCT06955169 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTOG Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intracranial Meningioma appearing as the primary indexed condition, and to 2 interventions - of which [177Lu]Lu-DOTATATE is the first listed.
NCT06955169 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT06955169 about?
NCT06955169 is a clinical study titled "Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment". This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
What is the current status of trial NCT06955169?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2025-12-24. Estimated completion is 2030-08.
What conditions does trial NCT06955169 study?
This clinical trial studies the following conditions: Intracranial Meningioma.
What interventions are being tested in trial NCT06955169?
The interventions under investigation include: [177Lu]Lu-DOTATATE (DRUG), Standard of Care treatments (OTHER).
Who is sponsoring clinical trial NCT06955169?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06955169 being conducted?
This trial has 3 study locations across Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracranial Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.